Anna Ter-Zakarian

Sep 21, 2023 | mdpi.com | Aaron Trando |Phillip Yeung |Aaron Goodman |Anna Ter-Zakarian

1. IntroductionChimeric antigen receptor T-cell (CAR T-cell) therapy has demonstrated groundbreaking success in treating multiple hematologic malignancies. CAR T-cell therapies are currently approved by the US Food and Drug Administration (FDA) for use in a number of diverse hematologic malignancies, from the very first approval of tisagenlecleucel (tisa-cel) for relapsed/refractory (R/R) acute lymphoblastic leukemia to there now being six approved CAR T-cell products [1,2].